Literature DB >> 10457267

Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells.

K Stewart1, S Walsh, J Screen, C M Jefferiss, J Chainey, G R Jordan, J N Beresford.   

Abstract

Primitive cells of the osteoblast lineage are not well characterized but are known to be present within the STRO-1+ fraction of adult human bone and marrow. A survey of human osteosarcoma cell lines revealed that STRO-1 is expressed by MG-63 but not SaOS-2. Among murine cell lines tested, expression of STRO-1 was detected in the bipotential (adipocyte/osteoblast) line BMS-2 but not the committed osteoblast precursor MC3T3-E1. A proportion of cultured adult human bone marrow stromal cells (BMSCs) consistently expressed the STRO-1 antigen. The expression of a range of cell surface antigens was studied in relation to STRO-1 by flow cytometry and several, including the bone/liver/kidney isoform of alkaline phosphatase (ALP), were found to subtype the STRO-1+ population of BMSCs. Further, BMSCs dual-labeled with antibodies recognizing STRO-1 and ALP could be assigned to one of four fractions: STRO-1-/ALP-, STRO-1+/ALP-, STRO-1+/ALP+, and STRO-1-/ALP+. Cells from each fraction could be isolated in high purity and, when recultured, remained viable and exhibited a limited degree of phenotypic stability. Using reverse transcriptase-polymerase chain reaction, cells in the four fractions were found to express different levels of transcripts for the parathyroid hormone receptor (PTHr) and bone sialoprotein (BSP). The expression of transcripts for the nuclear transcription factor core-binding factor alpha 1/osteoblast-specific factor-2 (CBFA1/OSF2) was restricted to those fractions expressing STRO-1 and/or ALP. Treatment with 10 nM dexamethasone consistently increased the proportion of cells present in those fractions which expressed the highest levels of transcripts for PTHr and BSP (STRO-1+/ALP+ and STRO-1-/ALP+) while simultaneously decreasing the proportion present in the STRO-1+/ALP- fraction. In conclusion, the expression of STRO-1 in vitro remains a characteristic of less well differentiated cells of the osteoblast lineage; in cultures of BMSCs and in established human osteosarcoma cell lines, there is an inverse association between the expression of STRO-1 and ALP; dual labeling of BMSCs with monoclonal antibodies recognizing STRO-1 and ALP permits the identification and isolation of cells of the osteoblast lineage at different stages of differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10457267     DOI: 10.1359/jbmr.1999.14.8.1345

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  46 in total

1.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.

Authors:  Guitty Eghbali-Fatourechi; Sundeep Khosla; Arunik Sanyal; William J Boyle; David L Lacey; B Lawrence Riggs
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

2.  A non-invasive method for in situ quantification of subpopulation behaviour in mixed cell culture.

Authors:  Ben D MacArthur; Rahul S Tare; Colin P Please; Philip Prescott; Richard O C Oreffo
Journal:  J R Soc Interface       Date:  2006-02-22       Impact factor: 4.118

Review 3.  Mesenchymal stem cells: lineage, plasticity, and skeletal therapeutic potential.

Authors:  Richard O C Oreffo; Cyrus Cooper; Christopher Mason; Mark Clements
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

4.  Selection using the alpha-1 integrin (CD49a) enhances the multipotentiality of the mesenchymal stem cell population from heterogeneous bone marrow stromal cells.

Authors:  David A Rider; Thenmozhi Nalathamby; Victor Nurcombe; Simon M Cool
Journal:  J Mol Histol       Date:  2007-08-11       Impact factor: 2.611

5.  Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.

Authors:  Gerald J Atkins; Peter S Rowe; Hui P Lim; Katie J Welldon; Renee Ormsby; Asiri R Wijenayaka; Lesya Zelenchuk; Andreas Evdokiou; David M Findlay
Journal:  J Bone Miner Res       Date:  2011-07       Impact factor: 6.741

Review 6.  Engineered Mesenchymal Stem Cells for Targeting Solid Tumors: Therapeutic Potential beyond Regenerative Therapy.

Authors:  Shen Cheng; Susheel Kumar Nethi; Sneha Rathi; Buddhadev Layek; Swayam Prabha
Journal:  J Pharmacol Exp Ther       Date:  2019-06-07       Impact factor: 4.030

7.  Induction of multipotency in umbilical cord-derived mesenchymal stem cells cultivated under suspension conditions.

Authors:  Fatemeh Amiri; Raheleh Halabian; Morteza Salimian; Mohammad Ali Shokrgozar; Masoud Soleimani; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Cell Stress Chaperones       Date:  2014-01-26       Impact factor: 3.667

8.  SHIP is required for a functional hematopoietic stem cell niche.

Authors:  Amy L Hazen; Michelle J Smith; Caroline Desponts; Oliver Winter; Katrin Moser; William G Kerr
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

9.  Osteolineage niche cells initiate hematopoietic stem cell mobilization.

Authors:  Shane R Mayack; Amy J Wagers
Journal:  Blood       Date:  2008-05-02       Impact factor: 22.113

Review 10.  Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine.

Authors:  G T-J Huang; S Gronthos; S Shi
Journal:  J Dent Res       Date:  2009-09       Impact factor: 6.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.